Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 2/2016

01.04.2016 | leitlinien für die praxis

Maturity onset diabetes of the young (MODY) – Screening, Diagnostik und Therapie

verfasst von: Susanne Kaser, Michael Resl

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Maturity onset diabetes of the young (MODY) stellt eine Gruppe an monogenetischen Diabetesformen dar, welche bis zu 2 % aller an Diabetes erkrankten Menschen betrifft. Mutationen der Transkriptionsfaktoren (HNF1α, HNF4α), welche gemeinsam auch die häufigste Ursache für MODY darstellen, erfordern meist eine entsprechende Therapie mit Sulfonylharnstoffen, während Mutationen des Glukokinase-Gens (GCK-MODY) üblicherweise keine Therapie erfordern. Die Konsequenz einer korrekten Diagnosestellung ist meist gerade bei jüngeren Menschen die Umstellung der Therapie von Insulin auf einen Sulfonylharnstoff bzw. das Beenden der Therapie bei Vorliegen eines GCK-MODY. Basierend auf der aktuell verfügbaren Literatur sollte gerade bei Patienten unter 25 Jahren mit positiver Familienanamnese und dem Fehlen von Autoantikörpern die Durchführung einer entsprechenden genetischen Untersuchung für MODY in Betracht gezogen werden.
Literatur
1.
Zurück zum Zitat Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes. 1975;24:44–53. CrossRefPubMed Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes. 1975;24:44–53. CrossRefPubMed
2.
Zurück zum Zitat Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med. 1974;43:339–57. PubMed Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med. 1974;43:339–57. PubMed
3.
Zurück zum Zitat Ellard S, Bellanne-Chantelot C, Hattersley AT, European Molecular Genetics Quality Network Mg. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51:546–53. CrossRefPubMedPubMedCentral Ellard S, Bellanne-Chantelot C, Hattersley AT, European Molecular Genetics Quality Network Mg. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51:546–53. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat McDonald TJ, Ellard S. Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem. 2013;50:403–15. CrossRefPubMed McDonald TJ, Ellard S. Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem. 2013;50:403–15. CrossRefPubMed
5.
Zurück zum Zitat Standards of medical care in diabetes–2015. Summary of revisions. Diabetes Care. 2015;38 Suppl:S4. Standards of medical care in diabetes–2015. Summary of revisions. Diabetes Care. 2015;38 Suppl:S4.
6.
Zurück zum Zitat Ledermann HM. Is maturity onset diabetes at young age (mody) more common in europe than previously assumed? Lancet. 1995;345:648. CrossRefPubMed Ledermann HM. Is maturity onset diabetes at young age (mody) more common in europe than previously assumed? Lancet. 1995;345:648. CrossRefPubMed
7.
Zurück zum Zitat Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T, et al. Phenotypical aspects of maturity-onset diabetes of the young (mody diabetes) in comparison with type 2 diabetes mellitus (t2dm) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009;26:466–73. CrossRefPubMed Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T, et al. Phenotypical aspects of maturity-onset diabetes of the young (mody diabetes) in comparison with type 2 diabetes mellitus (t2dm) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009;26:466–73. CrossRefPubMed
8.
Zurück zum Zitat Stride A, Hattersley AT. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med. 2002;34:207–16. CrossRefPubMed Stride A, Hattersley AT. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med. 2002;34:207–16. CrossRefPubMed
9.
Zurück zum Zitat McCarthy MI, Hattersley AT. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes. 2008;57:2889–98. CrossRefPubMedPubMedCentral McCarthy MI, Hattersley AT. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes. 2008;57:2889–98. CrossRefPubMedPubMedCentral
10.
11.
Zurück zum Zitat Martin D, Bellanne-Chantelot C, Deschamps I, Froguel P, Robert JJ, Velho G. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (mody2). Diabetes Care. 2008;31:1321–3. CrossRefPubMedPubMedCentral Martin D, Bellanne-Chantelot C, Deschamps I, Froguel P, Robert JJ, Velho G. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (mody2). Diabetes Care. 2008;31:1321–3. CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Feigerlova E, Pruhova S, Dittertova L, Lebl J, Pinterova D, Kolostova K, et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr. 2006;165:446–52. CrossRefPubMed Feigerlova E, Pruhova S, Dittertova L, Lebl J, Pinterova D, Kolostova K, et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr. 2006;165:446–52. CrossRefPubMed
13.
Zurück zum Zitat Velho G, Blanche H, Vaxillaire M, Bellanne-Chantelot C, Pardini VC, Timsit J, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 mody-2 families. Diabetologia. 1997;40:217–24. CrossRefPubMed Velho G, Blanche H, Vaxillaire M, Bellanne-Chantelot C, Pardini VC, Timsit J, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 mody-2 families. Diabetologia. 1997;40:217–24. CrossRefPubMed
14.
Zurück zum Zitat Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am J Obstet Gynecol. 2001;185:240–1. CrossRefPubMed Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am J Obstet Gynecol. 2001;185:240–1. CrossRefPubMed
15.
Zurück zum Zitat Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet. 1998;19:268–70. CrossRefPubMed Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet. 1998;19:268–70. CrossRefPubMed
16.
Zurück zum Zitat Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, Hattersley AT. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005;28:1751–6. CrossRefPubMed Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, Hattersley AT. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005;28:1751–6. CrossRefPubMed
17.
Zurück zum Zitat Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the hnf1a gene. Diabet Med. 2010;27:157–61. CrossRefPubMed Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the hnf1a gene. Diabet Med. 2010;27:157–61. CrossRefPubMed
18.
Zurück zum Zitat Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362:1275–81. CrossRefPubMed Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362:1275–81. CrossRefPubMed
19.
Zurück zum Zitat Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the hnf4a gene. PLoS Med. 2007;4:e118. CrossRefPubMedPubMedCentral Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the hnf4a gene. PLoS Med. 2007;4:e118. CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden HA, Lumb PJ, et al. Molecular genetics and phenotypic characteristics of mody caused by hepatocyte nuclear factor 4alpha mutations in a large european collection. Diabetologia. 2005;48:878–85. CrossRefPubMed Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden HA, Lumb PJ, et al. Molecular genetics and phenotypic characteristics of mody caused by hepatocyte nuclear factor 4alpha mutations in a large european collection. Diabetologia. 2005;48:878–85. CrossRefPubMed
21.
Zurück zum Zitat Edghill EL, Bingham C, Slingerland AS, Minton JA, Noordam C, Ellard S, Hattersley AT. Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: Support for a critical role of hnf-1beta in human pancreatic development. Diabet Med. 2006;23:1301–6. CrossRefPubMed Edghill EL, Bingham C, Slingerland AS, Minton JA, Noordam C, Ellard S, Hattersley AT. Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: Support for a critical role of hnf-1beta in human pancreatic development. Diabet Med. 2006;23:1301–6. CrossRefPubMed
22.
Zurück zum Zitat Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971–80. CrossRefPubMed Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971–80. CrossRefPubMed
23.
Zurück zum Zitat Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (hnf-1alpha) gene. Diabet Med. 1998;15:816–20. CrossRefPubMed Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (hnf-1alpha) gene. Diabet Med. 1998;15:816–20. CrossRefPubMed
24.
Zurück zum Zitat Fajans SS, Bell GI. Macrosomia and neonatal hypoglycaemia in rw pedigree subjects with a mutation (q268x) in the gene encoding hepatocyte nuclear factor 4alpha (hnf4a). Diabetologia. 2007;50:2600–1. CrossRefPubMed Fajans SS, Bell GI. Macrosomia and neonatal hypoglycaemia in rw pedigree subjects with a mutation (q268x) in the gene encoding hepatocyte nuclear factor 4alpha (hnf4a). Diabetologia. 2007;50:2600–1. CrossRefPubMed
Metadaten
Titel
Maturity onset diabetes of the young (MODY) – Screening, Diagnostik und Therapie
verfasst von
Susanne Kaser
Michael Resl
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0938-9

Weitere Artikel der Sonderheft 2/2016

Wiener klinische Wochenschrift 2/2016 Zur Ausgabe

leitlinien für die praxis

Adipositas und Typ 2 Diabetes

leitlinien für die praxis

Andere spezifische Diabetesformen